UAB Hematology Review 2021
CLL Management in Times of COVID-19: Frontline Acalabrutinib or Ven +/- Obi, Ibrutinib, How to Identify Barriers to Treatment Due to the Ongoing Pandemic?
By
UAB Hematology Review 2021
FEATURING
Mayur Narkhede
By
UAB Hematology Review 2021
FEATURING
Mayur Narkhede
Login to view comments.
Click here to Login